Successful Treatment of Pan-resistant Klebsiella Pneumoniae Pneumonia and Bacteraemia with a Combination of High-dose Tigecycline and Colistin

Overview

Journal J Med Microbiol

Specialty Microbiology

Date 2010 Aug 7

PMID 20688947

Citations 22

Authors

Romney M Humphries

Theodoros Kelesidis

Jennifer Dien Bard

Kevin W Ward

Debika Bhattacharya

Michael A Lewinski

Affiliations

Soon will be listed here.

Abstract

The spread of antimicrobial resistance among members of the Enterobacteriaceae is a significant clinical threat. We report the treatment of pan-resistant Klebsiella pneumoniae bacteraemia with combination tigecycline and colistin in a 49-year-old male and review available therapeutic options. Despite a poor prognosis, the patient recovered, but remains colonized with the pan-resistant isolate.

Citing Articles

Nutritional analysis and characterization of carbapenemase producing-Klebsiella pneumoniae resistant genes associated with bovine mastitis infected cow's milk.

Mr Saddam , Khan M, Jamal M, Rahman S, Qadeer A, Khan I PLoS One. 2023; 18(10):e0293477.

PMID: 37889925 PMC: 10610456. DOI: 10.1371/journal.pone.0293477.

Emergence of colistin-resistant gram-negative rods in intensive care units: A cross-sectional study from a developing country.

Syed B, Ishaque S, Imran A, Muslim O, Khalid S, Siddiqui A SAGE Open Med. 2022; 10:20503121221132358.

PMID: 36277441 PMC: 9583228. DOI: 10.1177/20503121221132358.

Nanotargeting of Resistant Infections with a Special Emphasis on the Biofilm Landscape.

Alabresm A, Chandler S, Benicewicz B, Decho A Bioconjug Chem. 2021; 32(8):1411-1430.

PMID: 34319073 PMC: 8527872. DOI: 10.1021/acs.bioconjchem.1c00116.

Antibody-recruiting protein-catalyzed capture agents to combat antibiotic-resistant bacteria.

Idso M, Akhade A, Arrieta-Ortiz M, Lai B, Srinivas V, Hopkins Jr J Chem Sci. 2021; 11(11):3054-3067.

PMID: 34122810 PMC: 8157486. DOI: 10.1039/c9sc04842a.

Pharmacokinetics of high-dose tigecycline in critically ill patients with severe infections.

De Pascale G, Lisi L, Ciotti G, Vallecoccia M, Cutuli S, Cascarano L Ann Intensive Care. 2020; 10(1):94.

PMID: 32661791 PMC: 7357259. DOI: 10.1186/s13613-020-00715-2.

References

Perez F, Endimiani A, Ray A, Decker B, Wallace C, Hujer K . Carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae across a hospital system: impact of post-acute care facilities on dissemination. J Antimicrob Chemother. 2010; 65(8):1807-18. PMC: 2904665. DOI: 10.1093/jac/dkq191. View

Le J, Castanheira M, Burgess D, McKee B, Iqbal R, Jones R . Clonal dissemination of Klebsiella pneumoniae carbapenemase KPC-3 in Long Beach, California. J Clin Microbiol. 2009; 48(2):623-5. PMC: 2815646. DOI: 10.1128/JCM.02397-09. View

Nordmann P, Cuzon G, Naas T . The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis. 2009; 9(4):228-36. DOI: 10.1016/S1473-3099(09)70054-4. View

Cunha B . Pharmacokinetic considerations regarding tigecycline for multidrug-resistant (MDR) Klebsiella pneumoniae or MDR Acinetobacter baumannii urosepsis. J Clin Microbiol. 2009; 47(5):1613. PMC: 2681882. DOI: 10.1128/JCM.00404-09. View

Vasilev K, Reshedko G, Orasan R, Sanchez M, Teras J, Babinchak T . A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae. J Antimicrob Chemother. 2008; 62 Suppl 1:i29-40. DOI: 10.1093/jac/dkn249. View

Scheetz M, Qi C, Warren J, Postelnick M, Zembower T, Obias A . In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2007; 51(5):1621-6. PMC: 1855572. DOI: 10.1128/AAC.01099-06. View

Kitchel B, Rasheed J, Patel J, Srinivasan A, Navon-Venezia S, Carmeli Y . Molecular epidemiology of KPC-producing Klebsiella pneumoniae isolates in the United States: clonal expansion of multilocus sequence type 258. Antimicrob Agents Chemother. 2009; 53(8):3365-70. PMC: 2715580. DOI: 10.1128/AAC.00126-09. View

Agwuh K, MacGowan A . Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother. 2006; 58(2):256-65. DOI: 10.1093/jac/dkl224. View

Kelesidis T, Karageorgopoulos D, Kelesidis I, Falagas M . Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. J Antimicrob Chemother. 2008; 62(5):895-904. PMC: 8445635. DOI: 10.1093/jac/dkn311. View

10.

Kochar S, Sheard T, Sharma R, Hui A, Tolentino E, Allen G . Success of an infection control program to reduce the spread of carbapenem-resistant Klebsiella pneumoniae. Infect Control Hosp Epidemiol. 2009; 30(5):447-52. DOI: 10.1086/596734. View

11.

Elemam A, Rahimian J, Mandell W . Infection with panresistant Klebsiella pneumoniae: a report of 2 cases and a brief review of the literature. Clin Infect Dis. 2009; 49(2):271-4. DOI: 10.1086/600042. View

12.

Falagas M, Kastoris A, Kapaskelis A, Karageorgopoulos D . Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis. 2010; 10(1):43-50. DOI: 10.1016/S1473-3099(09)70325-1. View

13.

Palacios G, Hornig M, Cisterna D, Savji N, Bussetti A, Kapoor V . Streptococcus pneumoniae coinfection is correlated with the severity of H1N1 pandemic influenza. PLoS One. 2010; 4(12):e8540. PMC: 2795195. DOI: 10.1371/journal.pone.0008540. View